Rezolute, Inc.

Equities

RZLT

US76200L3096

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-23 EDT			5-day change	1st Jan Change
3.06 ^USD	+8.90%		+15.47%	+208.31%

05-22	Traders Cautious Ahead of Fed Minutes, Nvidia Earnings, Stifling US Equity Futures Pre-Bell	MT
05-22	Top Premarket Gainers	MT

Rezolute, Inc. Announces the Addition of Adrian Vella to the Scientific Advisory Board

September 13, 2021 at 12:12 pm

Rezolute, Inc. announced the addition of Adrian Vella, MD, Professor of Medicine in the Endocrinology Division at the Mayo Clinic College of Medicine, to the company’s Scientific Advisory Board. Dr. Vella is a leading expert in hypoglycemic disorders and will provide guidance on the development of RZ358.

Latest news about Rezolute, Inc.

Traders Cautious Ahead of Fed Minutes, Nvidia Earnings, Stifling US Equity Futures Pre-Bell	05-22	MT
Top Premarket Gainers	05-22	MT
Transcript : Rezolute, Inc. - Special Call	05-21
Rezolute Reports Positive Topline Results in Study of Diabetic Macular Edema Treatment; Shares Surge After Hours	05-21	MT
Transcript : Rezolute, Inc. - Shareholder/Analyst Call	05-16
JonesTrading Starts Rezolute With Buy Rating, $10 Price Target	04-18	MT
Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	03-06	CI
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-13	CI
Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer	01-24	CI
Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	01-23	CI
Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema	12-13	CI
JMP Securities Adjusts Price Target on Rezolute to $7 From $8, Maintains Market Outperform Rating	11-14	MT
Rezolute, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-13	CI
Rezolute Announces Further Evidence of RZ358?s Efficacy in Tumor-Mediated Hyperinsulinism	23-10-11	CI
Rezolute, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-14	CI
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	23-09-14	CI
Cantor Fitzgerald Adjusts Price Target on Rezolute to $5 From $7, Maintains Overweight Rating	23-06-28	MT
Rezolute to Start Late-Stage Study in Congenital Hyperinsulinism in Europe, Other Places	23-06-27	MT
Transcript : Rezolute, Inc. - Special Call	23-06-27
Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358	23-06-27	CI
Transcript : Rezolute, Inc. - Shareholder/Analyst Call	23-05-25
Canaccord Genuity Adjusts Price Target on Rezolute to $17 From $16, Maintains Buy Rating	23-05-19	MT
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-11	CI
Rezolute, Inc. Announces KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema	23-03-23	CI
Transcript : Rezolute, Inc. - Special Call	23-03-22

Chart Rezolute, Inc.

Duration

Period

More charts

Company Profile

Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Companyâs lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Jefferies Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.06 USD

Average target price

10 USD

Spread / Average Target

+226.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REZOLUTE, INC.	+208.31%	113M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs